Cohance Lifesciences to invest USD 18 mn in NJ Bio, Aruka Bio

Cohance Lifesciences announced an eighteen million dollar investment to strengthen its antibody-drug conjugate strategy. This includes thirteen million dollars for NJ Bio, increasing Cohance's ownership to sixty-seven point three percent. An additional five million dollars will give Cohance a sixty-five percent stake in Aruka Bio. These transactions aim to integrate NJ Bio's services with Cohance's manufacturing capabilities. Completion of these strategic investments is expected by September twenty twenty-six.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/j7mLd9n
via IFTTT